MARKET

GBT

GBT

Global Blood
NASDAQ

Real-time Quotes | Nasdaq Last Sale

83.76
-3.44
-3.95%
After Hours: 85.00 +1.24 +1.48% 17:58 01/17 EST
OPEN
87.17
PREV CLOSE
87.20
HIGH
87.54
LOW
83.53
VOLUME
820.41K
TURNOVER
--
52 WEEK HIGH
87.54
52 WEEK LOW
43.69
MARKET CAP
5.04B
P/E (TTM)
-21.5521
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GBT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

GBT News

  • Morgan Stanley Maintains Equal-Weight on Global Blood Therapeutics, Raises Price Target to $80
  • Benzinga.17h ago
  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.18h ago
  • Hedge Fund Favorites vs. Global Blood Therapeutics Inc (GBT) In 2019
  • Insider Monkey.4d ago
  • The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
  • Benzinga.01/10 12:13

More

Industry

Biotechnology & Medical Research
-0.10%
Pharmaceuticals & Medical Research
+0.07%

Hot Stocks

Name
Price
%Change

About GBT

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
More

Webull offers Global Blood Therapeutics Inc (GBT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.